Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

BACKGROUND. Alcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts for 5% of deaths annually, and there is an urgent need to develop new targets for therapeutic intervention. The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodents and nonhuman primates, but its efficacy in patients with AUD is unknown.METHODS. In a randomized, double-blinded, placebo-controlled clinical trial, treatment-seeking AUD patients were assigned to receive exenatide (2 mg subcutaneously) or placebo once weekly for 26 weeks, in addition to standard cognitive-behavioral therapy. The primary outcome was reduction in number of heavy drinking days. A subgroup also completed functional MRI (fMRI) and single -photon emission CT (SPECT) brain scans.RESULTS. A total of 127 patients were enrolled. Our data revealed that although exenatide did not significantly reduce the number of heavy drinking days compared with placebo, it significantly attenuated fMRI alcohol cue reactivity in the ventral striatum and septal area, which are crucial brain areas for drug reward and addiction. In addition, dopamine transporter availability was lower in the exenatide group compared with the placebo group. Exploratory analyses revealed that exenatide significantly reduced heavy drinking days and total alcohol intake in a subgroup of obese patients (BMI > 30 kg/m2). Adverse events were mainly gastrointestinal.CONCLUSION. This randomized controlled trial on the effects of a GLP-1 receptor agonist in AUD patients provides new important knowledge on the effects of GLP-1 receptor agonists as a novel treatment target in addiction.TRIAL REGISTRATION. EudraCT: 2016-003343-11. ClinicalTrials.gov (NCT03232112).

Automated summary

This study provides new knowledge on the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, in patients with alcohol use disorder (AUD). Although exenatide did not significantly reduce the number of heavy drinking days compared to placebo, it attenuated fMRI alcohol cue reactivity and dopamine transporter availability in crucial brain areas for drug reward and addiction. In a subgroup of obese patients, exenatide significantly reduced heavy drinking days and total alcohol intake. Adverse events mainly consisted of gastrointestinal reactions.